Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments

Ann Rheum Dis. 2021 Jun;80(6):e94. doi: 10.1136/annrheumdis-2020-218244. Epub 2020 Jun 25.

Authors

Zoé Gendebien¹, Christian von Frenckell¹, Clio Ribbens¹, Béatrice André¹, Marie Thys², Marjorie Gangolf², Laurence Seidel², Michel G Malaise¹, Olivier Malaise³

Affiliations

¹ Rheumatology Department, University Hospital of Liège, Liège, Belgium.
² Medico-economic Information Department, University Hospital of Liège, Liège, Belgium.
³ Rheumatology Department, University Hospital of Liège, Liège, Belgium olivier.malaise@chuliege.be.

PMID: 32586921
DOI: 10.1136/annrheumdis-2020-218244

No abstract available

Keywords: glucocorticoids; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

Letter
Comment

MeSH terms

COVID-19 Drug Treatment*
Humans
Hydroxychloroquine / therapeutic use
Immunosuppressive Agents / therapeutic use
Lupus Erythematosus, Systemic* / complications
Lupus Erythematosus, Systemic* / diagnosis
Lupus Erythematosus, Systemic* / drug therapy

Substances

Immunosuppressive Agents
Hydroxychloroquine